Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Avacta Group Plc (AVCTF)
Wetherby, GB
Avacta Group Plc, a biopharmaceutical enterprise operating at the clinical stage, was established in 2003 and is headquartered in Wetherby, UK. The company specializes in the creation of cancer treatments and diagnostic solutions, leveraging its distinctive Affimer and pre|CISION proprietary platforms. Its operations span the United Kingdom, North America, South Korea, and broader regions of Asia and Europe, structured into two main divisions: Diagnostics and Therapeutics. The Diagnostics division is responsible for developing customized Affimer proteins for both external clients and its own diagnostic assays. This segment also manufactures the AffiDX SARS-CoV-2 rapid antigen lateral flow tests and supplies Affimer reagents for integration into other companies' products. Concurrently, the Therapeutics division focuses on advancing innovative cancer immunotherapies, strategically combining Avacta's proprietary technologies. Avacta has forged a variety of key partnerships and collaborations. These include a research alliance concerning its pre|CISION technology, which utilizes a substrate engineered for cleavage by fibroblast activation protein alpha; a drug development collaboration with LG Chem Life Sciences; a joint venture with Tufts University School of Medicine to progress Affimer drug conjugate therapies; a licensing deal with POINT Biopharma Inc. for the development of tumour-activated radiopharmaceuticals; and a drug development alliance with AffyXell to engineer mesenchymal stem cells for the treatment of autoimmune diseases.
Based on only 1 article — low confidence
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | +2.92% | +7.53% | +3.30% | +28.54% | +149.31% | -33.33% | -71.43% | -57.67% | -57.67% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
-
Revenue growth Biotechnology: +1.6%0.0% Q4'25: -99.5% (vs Q2'23)
-
EPS growth Biotechnology: +29.7%+39.7% ★ Q4'25: -14.3% (vs Q2'23)
-
FCF margin FCF growth · Biotechnology: +16.2%-32,101.1% Q4'25: -19,742.4% (vs Q2'23)
-
EBIT margin Biotechnology: +0.0%-26,756.8% Q4'25: -30,075.8% (vs Q2'23)
-
ROIC Biotechnology: -16.1%-5,619.9% Q4'25: -12,745.7% (vs Q2'23)
-
Share dilution Biotechnology: -3.4%+22.3% Q4'25: +62.2% (vs Q2'23)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.52× Q4'25: -0.22× (vs Q2'23)
| Metric |
Dec 2015 actual |
Dec 2016 actual |
Dec 2017 actual |
Dec 2018 actual |
Dec 2019 actual |
Dec 2020 actual |
Dec 2021 actual |
Dec 2022 actual |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
Dec 2026 1 Rev. Ana. 1 EPS Ana. |
Dec 2027 1 Rev. Ana. 1 EPS Ana. |
Dec 2028 1 Rev. Ana. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue |
1.81M
est: 3.12M (-41.9%)
|
2.17M
est: 2.89M (-25.0%)
|
2.74M
est: 3.63M (-24.6%)
|
2.76M
est: 3.94M (-29.8%)
|
4.12M
est: 4.11M (+0.4%)
|
3.64M
est: 5.47M (-33.5%)
|
2.94M
est: 6.08M (-51.7%)
|
9.65M
est: 9.31M (+3.7%)
|
23.25M
est: 29.39M (-20.9%)
|
113.0K
est: 23.02M (-99.5%)
|
113.0K
est: 2.12M (-94.7%)
|
30.98M
30.98M – 30.98M
+1,361.0% YoY
|
28.92M
28.92M – 28.92M
-6.7% YoY
|
191.2K
191.2K – 191.2K
-99.3% YoY
|
| EBITDA |
-2.58M
est: -3.12M (+17.1%)
|
-4.42M
est: -2.88M (-53.3%)
|
-6.40M
est: -3.62M (-76.8%)
|
-7.58M
est: -3.93M (-92.8%)
|
-9.08M
est: -4.10M (-121.5%)
|
-17.36M
est: -5.46M (-218.0%)
|
-26.69M
est: -6.07M (-339.5%)
|
-25.87M
est: -9.30M (-178.3%)
|
-23.05M
est: -29.34M (+21.4%)
|
-17.62M
est: -22.98M (+23.3%)
|
-28.95M
est: -2.12M (-1,267.6%)
|
-30.93M
-30.93M – -30.93M
-1,361.0% YoY
|
-28.87M
-28.87M – -28.87M
+6.7% YoY
|
-190.9K
-190.9K – -190.9K
+99.3% YoY
|
| EBIT |
-5.57M
est: -3.12M (-78.4%)
|
-5.66M
est: -2.89M (-96.1%)
|
-7.98M
est: -3.63M (-120.1%)
|
-10.43M
est: -3.94M (-165.1%)
|
-11.18M
est: -4.11M (-172.3%)
|
—
est: -5.47M (+100.0%)
|
-29.08M
est: -6.08M (-378.1%)
|
—
est: -9.31M (+100.0%)
|
-26.72M
est: -29.39M (+9.1%)
|
-19.13M
est: -23.02M (+16.9%)
|
-30.23M
est: -2.12M (-1,325.5%)
|
-30.98M
-30.98M – -30.98M
-1,361.0% YoY
|
-28.92M
-28.92M – -28.92M
+6.7% YoY
|
-191.2K
-191.2K – -191.2K
+99.3% YoY
|
| Net Income |
-9.99M
est: -17.25M (+42.1%)
|
-4.65M
est: -18.78M (+75.3%)
|
-6.37M
est: -28.66M (+77.8%)
|
-8.83M
est: -35.01M (+74.8%)
|
-9.68M
est: -30.69M (+68.4%)
|
-18.89M
est: -22.31M (+15.3%)
|
-26.32M
est: -29.54M (+10.9%)
|
-39.19M
est: -27.78M (-41.1%)
|
-24.95M
est: -33.46M (+25.5%)
|
-52.84M
est: -32.90M (-60.6%)
|
-38.37M
est: -25.30M (-51.7%)
|
-22.86M
-22.86M – -22.86M
+9.6% YoY
|
-20.13M
-20.13M – -20.13M
+11.9% YoY
|
—
— – —
+100.0% YoY
|
| SGA |
6.85M
est: 70.93M (-90.3%)
|
5.43M
est: 65.63M (-91.7%)
|
7.18M
est: 82.39M (-91.3%)
|
8.52M
est: 89.43M (-90.5%)
|
8.47M
est: 93.33M (-90.9%)
|
7.32M
est: 124.26M (-94.1%)
|
8.14M
est: 138.25M (-94.1%)
|
13.52M
est: 211.63M (-93.6%)
|
19.76M
est: 667.83M (-97.0%)
|
12.05M
est: 1.01B (-98.8%)
|
12.16M
est: 92.98M (-86.9%)
|
1.36B
1.36B – 1.36B
+1,361.0% YoY
|
1.27B
1.27B – 1.27B
-6.7% YoY
|
8.38M
8.38M – 8.38M
-99.3% YoY
|
| EPS |
-0.20
est: -0.05 (-278.9%)
|
-0.07
est: -0.06 (-19.4%)
|
-0.10
est: -0.09 (-11.4%)
|
-0.13
est: -0.11 (-21.4%)
|
-0.08
est: -0.09 (+14.4%)
|
-0.08
est: -0.07 (-22.6%)
|
-0.11
est: -0.09 (-21.7%)
|
-0.15
est: -0.08 (-76.5%)
|
-0.09
est: -0.10 (+10.6%)
|
-0.16
est: -0.08 (-94.5%)
|
-0.10
est: -0.06 (-52.6%)
|
-0.06
-0.06 – -0.06
+9.6% YoY
|
-0.05
-0.05 – -0.05
+11.9% YoY
|
—
— – —
+100.0% YoY
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-26 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-05-14 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
| 2026-04-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Christina Coughlin | Chief Executive Officer & Executive Director | 741.3K | — |
| Brian Hahn | Chief Financial Officer & Company Secretary | 499.1K | male |
| R. Craig Slater | Chief Operating Officer of Diagnostics | 92.8K | male |
| Emma Wright | Group In-House Counsel | — | female |
| Karen Harrison | Chief Operating Officer | — | female |
| Michael Vinegrad | Group Communications Director | — | male |
| Anne McGurk | Joint Managing Director of Launch Diagnostics | — | female |
| Sebastien Goenen | Chief Operating Officer of Coris BioConcept | — | male |
| David Liebowitz | Chief Medical Officer | — | — |
| David Wilson | Chief Commercial Officer of Diagnostics | — | male |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for AVCTF
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
